IOncology

Artificial Intelligence (AI) is transforming the diagnostic and treatment approaches for urological tumors, especially with significant advancements in intelligent imaging and pathology, potentially becoming an indispensable tool for clinicians. Dr. Vasileios Sakalis, a urologist from the Hippokrateion General Hospital of Thessaloniki, Greece, presented a comprehensive review on the application of AI in urological tumors at the conference. During an on-site interview with "Oncology Frontier-Urology Frontier," he shared further insights on the applications of AI.

The ASCO-GU, a premier academic conference in urologic oncology, at the beginning of the year sparked academic enthusiasm in 2024, receiving over 140 abstracts related to renal cell carcinoma (RCC). Professor Xiongjun Ye from the Chinese Academy of Medical Sciences Cancer Hospital presented a report on the significant progress in RCC treatment from the ASCO-GU at the 4th Yanqi Lake Conference of the Chinese Medical Association Urology Surgery Branch, summarizing the essence for all to appreciate.

The current treatment status of mHSPC patients in China and the need for further improvement have drawn attention. Recently, at the "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" held in Beijing, Professor Benkang Shi from Qilu Hospital of Shandong University shared insights on "Long-term Management of mHSPC Patients with Novel Hormonal Therapy Schemes." Following the conference, "Oncology Frontier - Urology News" invited Professor Benkang Shi to share insights on the diagnosis and treatment status of mHSPC, stratification of key populations, and personalized treatment

The "4th Annual Conference of the Urology Physicians Branch of the Chinese Medical Association (2024)" was successfully held in Beijing from April 13th to 14th. During the conference, Professor Qiang Wei from West China Hospital, Sichuan University, shared insights on "Standard Treatment of mHSPC in the Era of Novel Hormonal Therapy." Subsequently, "Oncology Frontier - Urology News" invited Professor Qiang Wei to discuss the significance of early initiation of novel hormonal therapy for mHSPC patients, the comparison between dual and triple therapy, and precise treatment selection strategies.

While CDK4/6 inhibitors plus endocrine therapy (ET) have become the standard first-line treatment for HR+/HER2- advanced breast cancer patients, there is currently no standardized recommendation for treatment strategies after progression on CDK4/6 inhibitors plus ET. At the "2024 National Breast Cancer Conference," "Oncology Frontier" had the privilege of inviting Professor Qingyuan Zhang from Harbin Medical University Cancer Hospital to discuss the factors to consider and the available treatment strategies for patients who have progressed on CDK4/6 inhibitors plus ET.

The "Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition)" ("CSCO BC Guidelines") have been updated again, incorporating richer evidence-based medicine from early to late stages, introducing more new treatment strategies and options. It has influenced the field of breast cancer treatment in China significantly. "Oncology Frontier" interviewed Professor Shaohua Zhang from The Fifth Medical Center of the People's Liberation Army General Hospital to discuss the highlights and clinical significance of the updated "CSCO BC Guidelines".

Currently, neoadjuvant therapy has become an optimized treatment modality for locally advanced and some early-stage breast cancers. It can optimize local surgery by downsizing tumors and provide efficacy and prognostic information to guide adjuvant therapy, thus improving survival. Moreover, it serves as an excellent platform for personalized treatment efficacy prediction and new drug development. Translational research based on neoadjuvant platforms has significant value in selecting benefiting populations, predicting effective regimens, and achieving personalized and precise treatments. At the "2024 National Breast Cancer Congress," Professor Yingying Xu from The First Affiliated Hospital of China Medical University delivered a speech titled "Reflections on Translational Research Based on Neoadjuvant Platforms," which we will introduce in this article.